Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

Marshelle S Warren,Steven G. Hughes,Walter Singleton,Mason Yamashita,Mark C. Genovese

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

2015

Marshelle S Warren
Steven G. Hughes
Walter Singleton
Mason Yamashita
Mark C. Genovese

Introduction This randomized, double-blind, phase II study evaluated the pharmacodynamics, safety and tolerability of ISIS 329993 (ISIS-CRPRx), an antisense oligonucleotide, in patients with active rheumatoid arthritis (RA).

Keywords:

Oligonucleotide
Immunology
Randomized controlled trial
Pharmacodynamics
Rheumatology
Rheumatoid arthritis
C-reactive protein
Sense (molecular biology)
Tolerability
Medicine
Internal medicine
Phases of clinical research
Pharmacology
antisense oligonucleotide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations